Publications by authors named "T Jojima"
Article Synopsis
- Imeglimin, a new antidiabetic medication, was tested as an add-on therapy to metformin in patients with type 2 diabetes to see how it affects glucose levels and variability over 24 hours.
- The study involved 30 patients using continuous glucose monitoring (CGM) for 14 days, with imeglimin introduced on day 7, measuring effects before and after treatment.
- Results showed a significant decrease in 24-hour average glucose levels and increased time spent within the target glucose range, indicating improved glycemic control and variability with imeglimin addition, especially in those with higher baseline HDL cholesterol levels.
Aims/introduction: In patients with diabetes, obesity is an aggravating factor for glycemic control and its vascular complications. However, the psychological and behavioral characteristics of those patients with obesity have not been fully clarified. This study investigated eating and coping behavior, personality traits, quality of life (QOL), and depression status in patients with diabetes with or without obesity.
View Article and Find Full Text PDFUnlabelled: Immune cell function is impaired in hyperglycemic patients with diabetes but thought to improve with normalization of blood glucose levels. In this study, we hypothesized that this improvement might involve changes in T cell function. We compared the peripheral T cell markers between the people with and without type 2 diabetes (T2D) admitted to our hospital for glycemic control, and then in patients with T2D before and after the improvement of hyperglycemia by inpatient treatment.
View Article and Find Full Text PDFArticle Synopsis
- A 47-year-old woman with myotonic dystrophy experienced poor glycemic control despite treatment with pioglitazone and insulin after a traumatic injury.
- The addition of a GLP-1 receptor agonist significantly improved her blood sugar levels, allowing for the eventual withdrawal of insulin.
- Genetic testing revealed a specific variant in the GLP1R gene, commonly found in Asia, which enhances insulin production in response to GLP-1 treatment, marking a unique case of myotonic dystrophy linked to this gene polymorphism in Japan.
Background: To investigate effects of empagliflozin on plasma amino acids in people with type 2 diabetes.
Research Design And Methods: In a randomized, active-controlled, open-label trial, 58 patients with type 2 diabetes were randomized to 10 mg/day empagliflozin ( = 29) or standard treatment without empagliflozin (control group, = 29) and treated for 12 weeks. We obtained blood samples at baseline and 12 weeks and assessed the plasma amino acid profile by liquid chromatography-mass spectrometry liquid chromatography.